Supernus Pharmaceuticals (0LB2) Ownership - Who Owns Supernus Pharmaceuticals?
Supernus Pharmaceuticals (0LB2) Ownership Overview
- 4.32% Insiders
- 34.83% Mutual Funds
- 0.96% Other Institutional Investors
- 28.08% ETFs
- 31.80% Public Companies and Individual Investors
The ownership structure of Supernus Pharmaceuticals (GB:0LB2) stock is a mix of institutional, retail, and individual investors. Approximately 63.88% of the company’s stock is owned by Institutional Investors, 4.32% is owned by Insiders, and 31.80% is owned by Public Companies and Individual Investors.
The ownership structure of Supernus Pharmaceuticals (GB:0LB2) stock is a mix of institutional, retail, and individual investors. Approximately 63.88% of the company’s stock is owned by Institutional Investors, 4.32% is owned by Insiders, and 31.80% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Mar 15, 2026 | Frederick Hudson | $271,725 | |
| Mar 09, 2026 | Frank Mottola | $87,074 | |
| Mar 09, 2026 | William Todd Horich | $483,797 | |
| Mar 08, 2026 | Georges Gemayel | $1,002,811 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Royce & Associates Llc | $9,827,528 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ishares | 6,681,507 | Institution | 11.48% | 285,768,054 |
| Delaware Group Equity Funds V | 5,828,792 | Institution | 10.01% | 249,297,434 |
| Vanguard | 5,381,041 | Institution | 9.24% | 230,147,124 |
| Vanguard Index Funds | 4,480,870 | Institution | 7.70% | 191,646,810 |
| Jack Khattar | 2,216,451 | Insider | 3.81% | 94,797,609 |
| Spdr | 1,287,149 | Institution | 2.21% | 55,051,363 |
| Dfa | 1,246,744 | Institution | 2.14% | 53,323,241 |
| Dfa Investment Dimensions Group Inc | 1,069,085 | Institution | 1.84% | 45,724,765 |
| Vanguard Explorer Fund | 870,341 | Institution | 1.49% | 37,224,485 |
| Michael Rockefeller | 708,276 | Institution | 1.22% | 30,292,965 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Delaware Group Equity Funds V | 5,828,792 | Institution | 10.01% | 249,297,434 |
| Vanguard Index Funds | 4,480,870 | Institution | 7.70% | 191,646,810 |
| Dfa Investment Dimensions Group Inc | 1,069,085 | Institution | 1.84% | 45,724,765 |
| Vanguard Explorer Fund | 870,341 | Institution | 1.49% | 37,224,485 |
| Fidelity Salem Street Trust | 698,549 | Institution | 1.20% | 29,876,941 |
| Fidelity Concord Street Trust | 584,846 | Institution | 1.00% | 25,013,863 |
| Loomis Sayles Funds Ii | 497,170 | Institution | 0.85% | 21,263,961 |
| Vanguard Scottsdale Funds | 379,870 | Institution | 0.65% | 16,247,040 |
| Vanguard Tax-managed Funds | 375,471 | Institution | 0.64% | 16,058,895 |
| T. Rowe Price Quantitative Management Funds, Inc. | 358,847 | Institution | 0.62% | 15,347,886 |
FAQ
Who Owns Supernus Pharmaceuticals (GB:0LB2)?
According to the latest TipRanks data, approximately 63.88% of the company's stock is held by institutional investors, 4.32% is held by insiders, and 31.80% is held by public companies and individual investors.
What percentage of Supernus Pharmaceuticals (GB:0LB2) stock is held by institutional investors?
According to the latest TipRanks data, approximately 63.88% of Supernus Pharmaceuticals (GB:0LB2) stock is held by institutional investors: 34.83% by mutual funds, 28.08% by ETFs and 0.96% by other institutional investors.
What percentage of Supernus Pharmaceuticals (GB:0LB2) stock is held by retail investors?
According to the latest TipRanks data, approximately 31.80% of Supernus Pharmaceuticals (GB:0LB2) stock is held by public companies and individual investors.
Who owns the most shares of Supernus Pharmaceuticals (GB:0LB2)?
iShares owns the most shares of Supernus Pharmaceuticals (GB:0LB2).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.